title: [A study on mental symptoms developing during the treatment of Parkinson's disease (author's transl)].
abstract: We studied on mental symptoms which developed during the treatment of Parkinson's disease. Hallucination, delusion, and/or delirious state were observed in 23 (22.8%) of 101 cases. The cases with mental symptoms were studied for the incidence, detail of the symptoms, and the factors involved in their development.
  
  
  RESULTS
  1) Mental symptoms were observed in 23 patients and the incidence tended to be highest in the patients in their sixties. 2) In classification of the cases with mental symptoms, 12 cases showed the change of visual experience as main symptom and 3 cases had delusion. In these two cases, disturbance of consciousness was minimum, if any. Eight cases showed delirious state. 3) As for mental symptoms, visual hallucination was most frequently observed. 4) Complication of hypertension and history of depressive state were more frequently observed in the cases with mental symptoms than in those without. 5) Mean daily dose of L-dopa upon the onset of mental symptoms was less than mean daily maximum dose in the cases without mental symptoms. 6) The cases with cerebral atrophy in CT had a tendency to develop mental symptoms. 7) The cases with abnormal EEG were liable to develop mental symptoms. 8) The cases with mental symptoms were more often complicated by dyskinesia than those without.
  
  
  CONCLUSIONS
  The incidence of mental symptoms during the treatment of Parkinson's disease tended to be high in the aged patients who had all or some of these findings as previous history of psychiatric illness, hypertension, cerebral atrophy and abnormal EEG.
mesh_terms: D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects; D003702:Delusions / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000150:complications; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology*
chemical_list: D007980:Levodopa; D000547:Amantadine